Outlook Therapeutics (OTLK) Tax Provisions (2015 - 2025)
Outlook Therapeutics (OTLK) posted quarterly Tax Provisions of -$1.6 million for Q3 2025, down 55722.46% quarter-over-quarter from $2800.0 in Q1 2025.
Outlook Therapeutics (OTLK) Tax Provisions (2015 - 2025) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Tax Provisions for 11 consecutive years, with -$1.6 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Tax Provisions changed N/A year-over-year to -$1.6 million; the TTM figure through Sep 2025 stood at -$1.6 million (down 55622.46% YoY), while the FY2025 annual figure was -$1.6 million, down 55622.46% from the prior year.
- Tax Provisions slipped to -$1.6 million in Q3 2025 per OTLK's latest filing, from $2800.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $2800.0 in Q1 2023 and bottomed at -$1.6 million in Q3 2025.
- Historically, Tax Provisions has averaged -$220604.1 across 5 years, with a median of $2000.0 in 2021.
- Annual changes were most pronounced in 2022 — Tax Provisions changed 0.0% — and 2023, when it soared 40.0%.
- Outlook Therapeutics' Tax Provisions stood at $2000.0 in 2021, then slumped by 60.0% to $800.0 in 2022, then jumped by 250.0% to $2800.0 in 2023, then changed by 0.0% to $2800.0 in 2024, then tumbled by 55722.46% to -$1.6 million in 2025.
- Business Quant data shows OTLK's Tax Provisions at -$1.6 million in Q3 2025, $2800.0 in Q1 2025, and $2800.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.56 Mn |
| Mar 31, 2025 | 2,800.00 |
| Mar 31, 2024 | 2,800.00 |
| Mar 31, 2023 | 2,800.00 |
| Sep 30, 2022 | 800.00 |
| Mar 31, 2022 | 2,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Sep 30, 2020 | -805.00 |
| Jun 30, 2020 | -3.27 Mn |
| Sep 30, 2019 | -2.63 Mn |
| Jun 30, 2019 | -777,500.00 |
| Sep 30, 2018 | -497,500.00 |
| Dec 31, 2017 | -3.15 Mn |
| Sep 30, 2017 | 398,500.00 |
| Dec 31, 2016 | 4,000.00 |
| Jun 30, 2016 | 500.00 |
| Mar 31, 2016 | 50,500.00 |
| Dec 31, 2015 | 52,000.00 |
| Sep 30, 2015 | 9,744.00 |
| Jun 30, 2015 | 120,000.00 |